ARRIVENT BIOPHARMA, INC.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-85.1M | $163.4M |
| FY2023 | — | $-153.2M | $150.4M |
| FY2024 | — | $257.7M | $74.3M |
| FY2025 | — | $307.2M | $45.5M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-85.1M | $163.4M |
| FY2023 | — | $-153.2M | $150.4M |
| FY2024 | — | $257.7M | $74.3M |
| FY2025 | — | $307.2M | $45.5M |